Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

3

Revenue 2014

Remicade

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Remicade was produced by Johnson & Johnson, Mitsubishi Tanabe Pharma and Merck & Co..

J&J files would-be prostate cancer blockbuster in US

J&J files would-be prostate cancer blockbuster in US

up and the threat of biosimilar competition to big-selling biologic drugs such as Remicade (infliximab) is becoming ‘more measured’.

Samsung deal with Takeda looks beyond biosimilars

Samsung deal with Takeda looks beyond biosimilars Samsung Bioepis has already been granted approvals for biosimilars of Amgen's Enbrel (etanercept), Johnson &Johnson's Remicade (infliximab) and Sanofi's Lantus (insulin glargine), and has filed for versions of

Merck & Co's Remicade biosimilar undercuts its US rivals

Merck & Co's Remicade biosimilar undercuts its US rivals Merck &Co's Remicade biosimilar undercuts its US rivals. Its version will be 35% cheaper than J&J's originator product. ... Pfizer and Celltrion's Inflectra (infliximab-dyyb) biosimilar was priced at a 15% discount to Remicade's $30, 000-a-year price tag.

Merck launches Remicade biosimilar in US, undercutting rivals

Merck launches Remicade biosimilar in US, undercutting rivals Merck launches Remicade biosimilar in US, undercutting rivals. J&J’s Remicade is 35% more expensive than the new biosimilar. ... Pfizer and Celltrion's Inflectra (infliximab-dyyb) biosimilar was priced at a 15% discount to Remicade's $30, 000-a-year

Biosimilars eat into J&J's Remicade sales

Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales. But its IL-23 inhibitor 'signals better times ahead'. ... The group's prescription drug division saw revenues fall 0.2% to $8.6bn, with big-selling immunotherapy Remicade (infliximab) contracting 14% to $1.53bn

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics